(Q43742085)

26 November 2017

Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas (English)

1 reference

26 November 2017

Ravi D Rao

1

1 reference

26 November 2017

Stephan D Thomé

2

1 reference

26 November 2017

Judith O'Fallon

3

1 reference

26 November 2017

John D Earle

4

1 reference

26 November 2017

Robert P Dinapoli

5

1 reference

26 November 2017

Jan C Buckner

6

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

International Journal of Radiation Oncology Biology Physics

26 November 2017

1 reference

26 November 2017

53

1 reference

26 November 2017

2

1 reference

26 November 2017

376-384

1 reference

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

An analysis of dose-effect relationship in the radiotherapy of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Misonidazole combined with hyperfractionation in the management of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Superfractionation radiation therapy in the treatment of malignant astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Biologic basis for altered fractionation schemes.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Radiation tolerance of the rat spinal cord: time-dose relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Super fractionation in glioblastoma multiforme-results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas. A pilot feasibility study of the Radiotherapy Group of the EORTC.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineli

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Accelerated hyperfractionated radiotherapy for malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902731-1

7 January 2021

10.1016/S0360-3016(02)02731-1

Identifiers

DOI

1 reference

26 November 2017

1 reference